Caris GPSai
Use
Caris GPSai analyzes genomic and transcriptomic data to match a tumor’s molecular signature to one or more of 90 cancer categories. It is designed to aid oncologists in managing Cancer of Unknown Primary (CUP) or cases with atypical clinical presentation or clinical ambiguity. The test provides insights into the tissue of origin, informing treatment planning and potentially improving diagnostic accuracy for cancers with clinical ambiguity.
Special Instructions
Caris GPSai can be added to any solid tumor order without additional cost or specimen requirements. Selection is made by indicating the appropriate box on the Caris requisition form, and results are included in the final Caris report.
Limitations
The accuracy of the Caris GPSai test is validated using neural networks trained on an expansive database, but it heavily relies on the quality of genomic data obtained. Changes in tumor biomarker characteristics over time due to disease progression and therapy might affect the results. Older specimens may not reflect current disease status, particularly due to the influence of prior treatments.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
10-14 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin Block
Collection Instructions
Molecular testing is performed after targeting tissues through manual microdissection.
Other tests from different labs that may be relevant